Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189956 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2ATML3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL25264994 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2ATML3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL30360115 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2ATML3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL31316767 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2ATML3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL19578925 | 0.87 | SMN1; SMN2 (0.35) | SMN1; SMN2ATML3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL2862463 | 0.86 | EEF2K (0.37) | SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL25265290 | 0.86 | — | — | |
| SCHEMBL30360143 | 0.86 | — | — | |
| SCHEMBL25188781 | 0.86 | — | — | |
| SCHEMBL25265291 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154173-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025096697-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180226-B2 | Spirotricycle RIPK1 inhibitors and methods of uses thereof | RIPK1, RIPK3, RIPK4 | SMN1; SMN2 4062/4885ATM 1642/4885L3MBTL1 2859/4885 |
| US-20230159558-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | RIPK1, RIPK3, RIPK4 | SMN1; SMN2 4062/4885ATM 1642/4885L3MBTL1 2859/4885 |
| US-20250154173-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | SMN1; SMN2 1667/4885ATM 1207/4885L3MBTL1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.